These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 36815507)

  • 1. Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID-19 in the Omicron variant era: A national cohort study in Iran.
    Jamaati H; Karimi S; Ghorbani F; Panahi Y; Hosseini-Baharanchi FS; Hajimoradi M; Malek R; Noorali S; Mokhtari M; Khoundabi B; Sadr M; Mohamadnia A; Zahraei SM; Hashemian SM; Dastan F; Mortaz E; Tayeri K; Behtaj F; Vaezi H; Forouzanfar MM; Shafaghi S
    J Med Virol; 2023 Mar; 95(3):e28607. PubMed ID: 36815507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of COVID-19 Vaccinations With Intensive Care Unit Admissions and Outcome of Critically Ill Patients With COVID-19 Pneumonia in Lombardy, Italy.
    Grasselli G; Zanella A; Carlesso E; Florio G; Canakoglu A; Bellani G; Bottino N; Cabrini L; Castelli GP; Catena E; Cecconi M; Cereda D; Chiumello D; Forastieri A; Foti G; Gemma M; Giudici R; Grazioli L; Lombardo A; Lorini FL; Madotto F; Mantovani A; Mistraletti G; Mojoli F; Mongodi S; Monti G; Muttini S; Piva S; Protti A; Rasulo F; Scandroglio AM; Severgnini P; Storti E; Fumagalli R; Pesenti A;
    JAMA Netw Open; 2022 Oct; 5(10):e2238871. PubMed ID: 36301541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients.
    Whittaker R; Bråthen Kristofferson A; Valcarcel Salamanca B; Seppälä E; Golestani K; Kvåle R; Watle SV; Buanes EA
    Clin Microbiol Infect; 2022 Jun; 28(6):871-878. PubMed ID: 35219807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Vaccination Status and Outcomes in Patients Admitted to the ICU With COVID-19.
    van Diepen S; McAlister FA; Chu LM; Youngson E; Kaul P; Kadri SS
    Crit Care Med; 2023 Sep; 51(9):1201-1209. PubMed ID: 37192450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of COVID-19 vaccines against ICU admission during Omicron surge in Saudi Arabia: a nationwide retrospective cohort study.
    Aldawish S; Abusaris R; Almohammadi E; Althobiti F; Albarrag A
    BMC Infect Dis; 2023 Oct; 23(1):746. PubMed ID: 37907859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avoidable intensive care unit resource use and costs of unvaccinated patients with COVID-19: a historical population-based cohort study.
    Bagshaw SM; Abbott A; Beesoon S; Zuege DJ; Wasylak T; Manns B; Nguyen TX
    Can J Anaesth; 2022 Nov; 69(11):1399-1404. PubMed ID: 35879485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival.
    Sevinc SA; Metin S; Basi NB; Ling J; Cinar AS; Oba S
    Epidemiol Infect; 2022 Feb; 150():e35. PubMed ID: 35135644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection of Two and Three mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized With COVID-19-VISION Network, August 2021 to March 2022.
    DeSilva MB; Mitchell PK; Klein NP; Dixon BE; Tenforde MW; Thompson MG; Naleway AL; Grannis SJ; Ong TC; Natarajan K; Reese SE; Zerbo O; Kharbanda AB; Patel P; Stenehjem E; Raiyani C; Irving SA; Fadel WF; Rao S; Han J; Reynolds S; Davis JM; Lewis N; McEvoy C; Dickerson M; Dascomb K; Valvi NR; Barron MA; Goddard K; Vazquez-Benitez G; Grisel N; Mamawala M; Embi PJ; Fireman B; Essien IJ; Griggs EP; Arndorfer J; Gaglani M
    J Infect Dis; 2023 Apr; 227(8):961-969. PubMed ID: 36415904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.
    Sacco C; Del Manso M; Mateo-Urdiales A; Rota MC; Petrone D; Riccardo F; Bella A; Siddu A; Battilomo S; Proietti V; Popoli P; Menniti Ippolito F; Palamara AT; Brusaferro S; Rezza G; Pezzotti P; Fabiani M;
    Lancet; 2022 Jul; 400(10346):97-103. PubMed ID: 35780801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics and outcomes of critically ill patients with one, two and three doses of vaccination against COVID-19 in Australia.
    Otto M; Burrell AJC; Neto AS; Alliegro PV; Trapani T; Cheng A; Udy AA;
    Intern Med J; 2023 Mar; 53(3):330-338. PubMed ID: 35841294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study.
    Chiew CJ; Premikha M; Chong CY; Wei WE; Ong B; Lye DC; Heng D; Lee VJ; Tan KB
    Lancet Infect Dis; 2023 Feb; 23(2):177-182. PubMed ID: 36182678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of prior vaccination with Covishield
    Abhilash KPP; Mathiyalagan P; Krishnaraj VRK; Selvan S; Kanagarajan R; Reddy NP; Rajendiran N; Hazra D; Gunasekaran K; Moorthy M; Jasmine S; Davis JP; George T; George K; Varghese GM; Rupali P; Barney Isaac TJ; Gupta R; Pichamuthu K; Joy M; Jayaseelan L; Mathews P; Peter JV
    Vaccine; 2022 Mar; 40(13):2107-2113. PubMed ID: 35168837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 vaccinations and rates of infections, hospitalizations, ICU admissions, and deaths in Europe during SARS-CoV-2 Omicron wave in the first quarter of 2022.
    Rzymski P; Kasianchuk N; Sikora D; Poniedziałek B
    J Med Virol; 2023 Jan; 95(1):e28131. PubMed ID: 36068643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination status of COVID-19 patients followed up in the ICU in a country with heterologous vaccination policy: A multicenter national study in Turkey.
    Yıldırım S; Erkoyun E; Alpdoğan Ö; Yılmaz HO; Yılmaz B; Erdal Dönmez G; Sarıtaş A; Gökmen N; Ergan B; Bayrak V; Yakar MN; Kılıç Ö; Kılınç A; Saygılı S; Gaygısız Ü; Aydın K; Özel Yeşilyurt A; Cankar Dal H; Bayındır Dicle Ç; Turan S; Binay S; Yarıcı M; Yıldırım F; Hancı P; İnal MT; Akbaş T; Eyüpoğlu S; Albayrak T; Koçak G; Çakır T; Yüksel RC; Sarı A; Güneş M; Menteş O; Yamanel HL; Kirakli C
    J Infect Chemother; 2023 Oct; 29(10):959-964. PubMed ID: 37343924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort Study.
    Muhsen K; Maimon N; Mizrahi A; Bodenheimer O; Cohen D; Maimon M; Grotto I; Dagan R
    Clin Infect Dis; 2022 Aug; 75(1):e755-e763. PubMed ID: 34698808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
    Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
    Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
    Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
    Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population.
    Butt AA; Talisa VB; Yan P; Shaikh OS; Omer SB; Mayr FB
    Clin Infect Dis; 2022 Aug; 75(1):e579-e584. PubMed ID: 35245940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.